IFF's Scent recovery is anchored in a rebuilt R&D engine and stronger go-to-market execution, with near-term tailwinds from fragrance ingredients. 2H 2026 guidance shows Fine Fragrance accelerating into Q4 while Consumer Fragrance normalizes to low single-digit growth, as Middle East volatility subsides. The 2027 plan focuses on a robust pipeline and higher-value ingredient mix to sustain competitive advantage.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management attributes the turnaround to a sustained rebuild of Scent’s R&D engine: they highlight that 2.5 years ago the R&D pipeline “was not what it should have been,” whereas today they describe a “very strong R&D capability,” leading-edge perfumers, and a “great pipeline of molecules as well as delivery systems.” 1
They add that this R&D progress is now producing a credible pipeline that supports leadership in both Fine Fragrances and Consumer Fragrances. 1
The recovery is also tied to rebuilding commercial execution with customers. Management specifically points to a rebuild of the “R&D capability [and] go-to-market approach with customers” to drive market share gains in Consumer Fragrance. 2
For Fine Fragrance, the recovery is framed as a stabilization after Middle East-related uncertainty and volatility. Management says the team managed the challenges in the Middle East such that Fine Fragrance ended slightly positive versus expectations of mid-single-digit declines. 3
They also emphasize that while the Middle Eastern crisis continues, they are factoring in a softer Q3 and then expect recovery as they get to Q4. 3
Consumer Fragrance recovery is described less as a “shock reversal” and more as an expected normalization after a strong quarter. Management states Consumer Fragrance grew high single digits in Q2 but expects it to normalize toward a low single-digit range going forward (i.e., the recovery momentum continues but at a more normalized growth rate). 2
While the question is about Scent’s recovery and the two Scent sub-segments, the excerpts also show a key contributor to near-term Scent performance: Fragrance Ingredients grew north of 20% in Q2, aided by both an easy year-over-year comparison (vs. a down period “down 10% or more” in the prior year) and strategic use of synthetics amid macro and supply-chain conditions. 3
Management expects this to normalize and that growth will shift back toward higher-value-added ingredients versus traditional synthetics—an important medium-term positioning driver for later-year recovery and competitiveness. 3
Management gives a directional cadence for Fine Fragrance:
This is consistent with the Middle East framing: Q3 softness is explicitly “factored in,” and the improvement is expected later, especially into Q4. 3
Management’s guidance is:
So, relative evolution in 2H is:
Management emphasizes tangible improvements in the R&D system:
The excerpts explicitly connect product science and delivery systems to commercial execution:
This matters for 2027 because the mechanism for sustained recovery is not only innovation but also conversion into customer wins and share.
Although the “R&D to support 2027” question is asked in the context of Scent (and fine/consumer), the excerpt also signals a later-year competitiveness benefit from changing Fragrance Ingredients composition:
That longer runway aligns with 2027 being a period where both innovation outcomes (R&D pipeline) and ingredient mix strategy converge.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF attributes Scent’s rebound to a rebuilt R&D engine, stronger perfumers, and improved go-to-market execution, while guiding a softer Q3 and stronger Q4 for Fine Fragrance and a normalized low single-digit path for Consumer Fragrance in 2H. The company also emphasizes an expanded R&D program—molecules, delivery systems, and higher-value ingredients—to sustain growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a strengthened R&D pipeline and a revamped go-to-market strategy, with Consumer Fragrance poised for market-share gains while Fine Fragrance navigates regional volatility. The company frames 2027 as a natural extension of its enhanced R&D capabilities, with a shift toward higher-value, natural ingredients and sustained innovation to support growth in the second half and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi‑driver path to Scent recovery, led by Fragrance Ingredients momentum, improved Consumer and Fine Fragrance execution, and an R&D overhaul aimed at 2027. In 2H, Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes from a high single-digit Q2 growth to a low single-digit trajectory, supported by a revamped product pipeline and go‑to‑market strategy.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, stabilization in Fine Fragrance, and a rebuilt Consumer Fragrance engine anchored by R&D and go-to-market improvements. The 2H 2026 path points to a Q3 softness followed by a Q4 rebound, with a longer runway toward 2027 supported by an 8–9% R&D intensity and a strengthened innovation pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by strong Fragrance Ingredients growth and a rebuilt R&D engine, with a mid-to-long-term plan to enhance market position into 2027. In H2, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance trends toward low single-digit growth as R&D and go-to-market initiatives support share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to robust Fragrance Ingredients growth and an improved R&D pipeline, with plans to support 2027. Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes to a low single-digit growth profile.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound in Q2 2026 rests on normalization of Fragrance Ingredients, resilient Fine Fragrance execution amid Middle East volatility, and a rebuild of R&D and go-to-market for Consumer Fragrance. Management signals a mid‑single‑digit H2 for Fine Fragrance and low single-digit growth for Consumer Fragrance, underpinned by an improved R&D pipeline and a long-term push into 2027 with higher-value ingredients and delivery systems.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 results underscore a resilient Scent recovery driven by double-digit Fragrance Ingredients growth and solid Consumer Fragrance momentum, with a rebuilt R&D pipeline set to support growth into 2027. In the second half, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace as R&D and go-to-market improvements support market share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management attributes Scent's rebound to a rebuilt R&D engine and stronger go-to-market execution, with 2H expected to show mid-single-digit growth for Fine Fragrance and low-single-digit gains for Consumer Fragrance, while Fragrance Ingredients normalizes. The plan emphasizes sustained R&D investment around 8-9% of sales to support a pipeline of molecules, delivery systems, and innovative products through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, a cautious but improving Fine Fragrance trajectory through Middle East volatility, and a Consumer Fragrance rebound driven by rebuilt R&D and go-to-market capabilities aimed at market-share gains. The plan emphasizes a multi-year R&D rebuild, a deep pipeline of molecules and delivery systems, and an innovation-first path to 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent's rebound to Fragrance Ingredients momentum, with Fine Fragrance stabilizing amid volatility and Consumer Fragrance propelled by an R&D-led recovery and go-to-market rebuild. The company expects a mid-single-digit 2H for Fine Fragrance and a low single-digit pace for Consumer Fragrance, supported by a strengthened R&D pipeline targeting 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-faceted Scent recovery driven by stabilizing Fine Fragrance demand, normalization of Consumer Fragrance through revamped R&D and go-to-market execution, and a shift toward higher-value Fragrance Ingredients. The firm also details a robust 2027 R&D plan designed to sustain competitive advantage with an strengthened pipeline, leading-edge perfumers, and sustained reinvestment in innovation, aligned to long-term growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi